Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study

Table 5 Clinical Characteristics of the Three Groups with SARS-CoV-2 Pneumonia

	Total (n = 93)	UV (n = 35)	PV (n = 19)	FV (n = 39)	P
Gender					0.452
Male, No. (%)	42 (45.2)	15 (42.9)	11 (57.9)	16 (41)
Female, No. (%)	51 (54.8)	20 (57.1)	8 (42.1)	23 (59)
Age, years	53 ± 16.37	55.63 ± 20.04	55.32 ± 17.53	49.51 ± 11.06	0.219
BMI, kg/m²	22.77 ± 2.93	23.22 ± 3.56	21.76 ± 2.58	22.86 ± 2.36	0.211
Smoking, No. (%)	37 (39.8)	12 (31.4)	8 (42.1)	18 (46.2)	0.422
Comorbidities, No. (%)	54 (58.1)	25 (71.4)	11 (57.9)	18 (46.2)	0.089
Treatment
Thymosin α1, No. (%)	22 (23.7)	6 (16.7)	3 (15.8)	13 (33.3)	0.174
Days from illness onset to hospital admission	2 (1–3)	2 (1–3)	2 (1–4)	2 (1–3)	0.880
Ct value	28.98 ± 5.93	27.68 ± 5.45	29.15 ± 6.92	30.07 ± 5.75	0.225
IVOR, days	1 (− 1–4)	2 (− 1–5)	0 (-1–4)	1 (− 2–4)	0.555
IL-6, pg/ml	14.6 (8.3–28.2)	13.4 (8.2–28.8)	19.3 (13.2–34.4)	13.9 (8–25.3)	0.454
IVORD, No. (%)	60 (64.5)	21 (60)	14 (73.7)	25 (64.1)	0.603

Data are presented as median (interquartile range) or mean ± standard deviation or the number (percentage). Continuous variables were analyzed by variance analysis or Kruskal‒Wallis test. Categorical variables were compared using the chi-square (χ²) test or Fisher’s exact test. A P value of less than 0.05 (two-tailed) was considered statistically significant
FV fully vaccinated, PV partially vaccinated, UV,= unvaccinated, ct SARS-CoV-2 nucleocapsid gene cycle threshold (ct) value, IVOR the time interval from viral RNA shedding to the onset of pneumonia lesion reduction on CT, IL-6 interleukin-6, IVORD the time interval from viral RNA shedding to the onset of pneumonia lesion reduction on CT within − 3 to 3 days

ISSN: 1471-2334